PROTOKINETIX BLOG

Find out how AAGP® is changing lives through cell survival

As we move forward with clinical research for our anti-aging glycopeptide, AAGP®, we continue to uncover new areas of opportunity for the molecule. See how AAGP® is helping to provide more hope for patients and investors in the areas of ophthalmology, transplants, dermatology and biomanufacturing.

Jul 07, 2020

bybhenderson

dry-eye

ProtoKinetix AAGP® Dry Eye Program Advancing

Marietta, Ohio, July 7, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, provides the following update regarding upcoming news in its Dry Eye...Read more

Apr 06, 2020

bybhenderson

dry-eye

ProtoKinetix AAGP® Exhibits Efficacy and Safety in Model of Dry Eye Disease

Marietta, Ohio, April 6, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX), a clinical-stage biomedical company, having recently announced filing for patent protection for new applications of...Read more

Mar 24, 2020

bybhenderson

ProtoKinetix Ready to Ship AAGP® to the University of Alberta for the Continuation of Phase 1 Human Trials

Marietta, Ohio, March 24, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX), a clinical-stage biomedical company, today announced an update to the Press Release of January 24, 2020....Read more

Mar 19, 2020

bybhenderson

dry-eye

ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Marietta, Ohio, March 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule. During recent testing conducted by...Read more

Feb 19, 2020

bybhenderson

ProtoKinetix Announces Progress in the use of AAGP® in Cardiovascular Medicine

Marietta, Ohio, Feb. 19, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that...Read more

Feb 11, 2020

bybhenderson

ProtoKinetix files for Patent protection for the use of AAGP® in transplant medicine

Marietta, Ohio, February 11, 2020 ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) recently filed for patent protection for a new application of its AAGP® molecule. During recent...Read more

Jan 24, 2020

byncaipen

Transplants

ProtoKinetix Takes Delivery of GMP AAGP® PKX-001 Dedicated for Phase 1 Trial

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that the Company has taken procession of an additional 200 grams of GMP grade PKX-001 (AAGP®) molecule. We are...Read more

Jan 06, 2020

byncaipen

Ophthalmology

ProtoKinetix AAGP® Dry Eye Therapy Testing Results

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces that ITR Laboratories of Montreal have run multiple tests on eye irritation at maximum concentration of AAGP® and to...Read more

Dec 19, 2019

byncaipen

Ophthalmology

ProtoKinetix AAGP® Retinal Cell Replacement Therapy Testing at UBC Completed

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the completion of an in vivo study to assess the effect of AAGP® on the long term survival and...Read more

Nov 22, 2019

byncaipen

Ophthalmology

ProtoKinetix AAGP® Dry Eye Therapy Program Launched

Marietta, Ohio ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) announces the initiation of a program testing AAGP®, to develop a potential therapy to treat Dry Eye Disease (DED). AAGP®...Read more

Request More Information

Talk to a member of the ProtoKinetix team to learn more about our research and results.